This is the standing evidence sheet for Regeneron Pharmaceuticals (REGN): the yardsticks BullScope computes from official SEC filings and market prices. It refreshes whenever a new edition of our research is published, and it is impersonal by design, every reader sees the same page. Nothing here is investment advice; it is the evidence, organized.
The price tag: what buyers pay per dollar of profit
Today the market pays about $15.3 for each $1 of Regeneron Pharmaceuticals’s annual profit (a price-to-earnings ratio of 15.3). Across its own past decade the typical price tag was 16.0, which puts today at roughly the 43th percentile of the company’s own history.
The tape: what the stock itself has done
- Last price: $738.72 (end-of-day market data as of the edition date · methodology) · 13% below its 52-week high
- Past 6 months: -2.8% · past 12 months: +23.1%
- Day-to-day temperament: jumpy (annualized volatility 33%)
The filed record: straight from the annual reports
| Fiscal year | Revenue | Growth | Operating margin | EPS |
|---|---|---|---|---|
| FY2021 | $16.1B | , | 55.7% | $71.97 |
| FY2022 | $12.2B | -24.3% | 38.9% | $38.22 |
| FY2023 | $13.1B | +7.8% | 30.9% | $34.77 |
| FY2024 | $14.2B | +8.3% | 28.1% | $38.34 |
| FY2025 | $14.3B | +1.0% | 24.9% | $41.48 |
The road ahead: filed results vs published expectations
| FY2023A | FY2024A | FY2025A | FY2026E | FY2027E | |
|---|---|---|---|---|---|
| Net sales ($B) | 13.1 | 14.2 | 14.3 | 15.3 to 16.5 | 15.8 to 18.0 |
| Net sales growth (%) | +5.6 | +8.4 | +0.7 | 7 to 15 | 5 to 9 |
| Operating margin (%) | 30.5 | 28.2 | 25.2 | 24 to 27 | 22 to 27 |
| Diluted EPS ($) | 34.77 | 38.34 | 41.48 | 42 to 52 | 40 to 58 |
Columns marked A are actual filed results; E columns are the published consensus ranges the current price is being weighed against.
The four gauges: from the latest edition
BullScope coverage of Regeneron Pharmaceuticals
- Regeneron Is Earning More Than Ever. The Stock Acts Like It Barely Noticed.
- One Drug Carries the Weight: What Regeneron’s Filed Numbers Say About the Price
Read the full report on Regeneron Pharmaceuticals in the BullScope Terminal → It opens with this company loaded.
Edition date: 2026-10-07. This page updates when a new edition is published. Sources: SEC EDGAR filings, Nasdaq prices; computed by BullScope’s published methodology.
